

1FW



Docket No.: 68970-235077  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<hr/>	
In re Patent Application of: Francisco Javier Vila Pahi et al.	Art Unit: Not Yet Assigned
Application No: 10/590,311	Examiner: Not Yet Assigned
Confirmation No: Not Yet Assigned	
Filed: August 23, 2006	Atty. Docket No: 68970-235077
For: NEW THERAPEUTIC USE FOR A GROUP OF SULPHATED POLYSACCHARIDES	Customer No: <b>*26694*</b> <small>PATENT TRADEMARK OFFICE</small>

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This is an Information Disclosure Statement submitted under 37 C.F.R. § 1.97 within the time specified under 37 C.F.R. § 1.97(b).

In order to comply with applicant's duty of disclosure under 37 C.F.R. § 1.56, the U.S. Patent and Trademark Office is notified of the documents which are listed on the attached Form PTO/SB/08A and which the Examiner may deem relevant to patentability of the claims of the above-identified application. Copies of the documents are submitted herewith.

It is believed that no fee is due for the submission of this Information Disclosure Statement. However, if any additional fee is required, please charge any necessary fee or credit any

Application No.: 10/590,311

Docket No.: 68970-235077


overpayment in connection with this Information Disclosure Statement to Deposit Account No. 22-0261.

Dated:

*Feb 12 2007*

Respectfully submitted,

By

  
Marina V. Schneller

Registration No.: 26,032

VENABLE LLP

P.O. Box 34385


Washington, DC 20043-9998

(202) 344-4000

(202) 344-8300 (Fax)

Attorney/Agent For Applicant

DC2DOCS1/827819



PTO/SB/17 (07-06)

Approved for use through 01/31/2007. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Effective on 12/08/2004.</b> <b>Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).</b>		<b>Complete if Known</b>	
<b>FEE TRANSMITTAL</b> <b>For FY 2006</b>		Application Number	10/590,311
		Filing Date	August 23, 2006
		First Named Inventor	Francisco J. Vila Pahi
		Examiner Name	Not Yet Assigned
		Art Unit	Not Yet Assigned
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27	Attorney Docket No.	68970-235077	
<b>TOTAL AMOUNT OF PAYMENT</b>		<b>(\$)</b>	0.00

**METHOD OF PAYMENT (check all that apply)**

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): \_\_\_\_\_

☒ Deposit Account Deposit Account Number: 22-0261 Deposit Account Name: Venable LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

**FEE CALCULATION****1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

**2. EXCESS CLAIM FEES**

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

Total Claims      Extra Claims      Fee (\$)      Fee Paid (\$)

25      - 25 =      x      =

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims      Extra Claims      Fee (\$)      Fee Paid (\$)

4      - 4 =      x      =

HP = highest number of independent claims paid for, if greater than 3.

**3. APPLICATION SIZE FEE**

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets      Extra Sheets      Number of each additional 50 or fraction thereof      Fee (\$)      Fee Paid (\$)

\_\_\_\_\_ - 100 = \_\_\_\_\_ / 50 \_\_\_\_\_ (round up to a whole number) x \_\_\_\_\_ = \_\_\_\_\_


**4. OTHER FEE(S)**

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): \_\_\_\_\_

<b>SUBMITTED BY</b>			
Signature		Registration No. (Attorney/Agent)	26,032
Name (Print/Type)	Marina V. Schneller	Telephone	(202) 344-4000
		Date	2/12/07

DC2DOCS1/827822



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/590,311
				Filing Date	August 23, 2006
				First Named Inventor	Francisco Javier Vila PAHL et al.
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	68970-235077

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA				
	AB				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA					
	BB					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	JORDAN, K.M. et al., "EULAR Recommendations 2003: An Evidence Based Approach to the Management of Knee Osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT); <i>Ann Rheum Dis.</i> 2003; 62, 1145-1155.		
	CB	ALTMAN, R. et al., "Development of Criteria for the Classification and Reporting of Osteoarthritis", <i>Arthritis and Rheumatism</i> , Vol. 29, No. 8, August 1986, pp. 1039-1049.		
	CC	KLIPPEL, John H. et al., "Osteoarthritis and Related Disorders", <i>PNEUMATOLOGY</i> , 2 <sup>ND</sup> Ed.,		
	CD	LEQUESNE, M., "Symptomatic Slow-Acting Drugs in Osteoarthritis: A Novel Therapeutic Concept?", <i>Expansion Scientifique Francaise</i> , 1994, 69-73.		
	CE	HARRIS, Edward D., RHEUMATOID ARTHRITIS, "Pathophysiology and Implications of Therapy", <i>The New England Journal of Medicine</i> , Vol. 322, No. 18, May 3, 1990, pps. 1277-1289.		
	CF	HOCHBERG, Marc C., "Adult and Juvenile Rheumatoid Arthritis: Current Epidemiologic Concepts", <i>EPIDEMIOLOGIC REVIEWS - THE JOHNS HOPKINS UNIVERSITY SCHOOL OF HYGIENE AND PUBLIC HEALTH</i> , Vol. 3, 1981, pp. 27-44.		
	CG	Committee for Proprietary Medicinal Products (CPMP), "Points to Consider on Clinical Investigation of Medicinal Products Other than NSAIDS for Treatment of Rheumatoid Arthritis", <i>The European Agency for the Evaluation for Medicinal Products</i> , London, December 17, 2003.		
	CH	COMBE, Bernard et al., "Eular Recommendations for the Management of Early Arthritis: Report of a Task Force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)", <i>Ann Rheum Dis.</i> , ARD Online First, published January 5, 2006, <a href="http://www.ard.bmjournals.com">www.ard.bmjournals.com</a> , pps. 1-24.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
-----------------------	--------------------

DC2DOCS1/827812